Herpes Zoster, HIV Infections, Neuralgia, Pain, Peripheral Nervous System Diseases
Conditions
Keywords
Analgesics, Capsaicin, Neuropathic pain, Neuropathy, PHN, Shingles
Brief summary
The purpose of the study is to evaluate the safety and efficacy of NGX-4010 administered at intervals of no less than 12 weeks over 1 year, based on the presence or return of pain, for the treatment of painful HIV-AN and PHN. Participation is limited to former study subjects from previous trials of NGX-4010 at selected sites.
Detailed description
Study C118 is a multicenter, open-label, single-arm study for subjects who successfully completed a previous NGX-4010 study and have not received open-label or blinded NGX-4010 study patches within the 12 weeks prior to study entry. One hundred eligible subjects will receive an initial open-label NGX-4010 study patch application and up to three additional open-label NGX-4010 applications at intervals of no less than 12 weeks, based on the presence or return of pain. Eligible subjects will have moderate to severe neuropathic pain secondary to HIV-AN or PHN, with average pain levels deemed appropriate for further treatment with NGX-4010 as judged by the Investigator.
Interventions
Sponsors
NeurogesX
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Summary eligibility criteria: * Subjects must be in good health and have successfully completed a past trial of NGX-4010 with no past occurrence of adverse events that would contraindicate further treatment. * The time between the last study patch on the previous study and the first study patch on this study must be at least 12 weeks. * Topical pain medications are exclusionary and require washout prior to study patch application for this study. * Chronic, nontopical pain medications are allowed but must be stable (not as needed) for a defined period prior to first study patch application. * Other specific inclusion and
Exclusion criteria
must be met prior to enrollment on the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean percent change from baseline in average pain for the past 24 hours NPRS score (i.e., average of scores during Weeks 12 and 48, compared to baseline). | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects who score 2 or 3 (Much Improved or Very Much Improved) on Patient Impression of Change at Weeks 12, 24, 36 and 48. | — |
| Proportion of subjects with significant changes in concomitant pain medication usage during the 2nd through 12th week following study patch application. | — |
Outcome results
None listed